Russians say Sputnik Light vaccination could complement Pfizer's use

Russians say Sputnik Light vaccination could complement Pfizer's use

Moscow, Aug 21 (Prensa Latina) The proposal to apply an additional dose of the Russian Sputnik Light Covid-19 vaccine to those immunized with the drug Pfizer (United States) would help improve the effect, the director of the Gamaleya Center, Alexandr Ginzburg, indicated.

Pfizer has a problem with the Delta strain, which now represents 90 percent, and in some regions of the world even 100 percent of total infections by the SARS-CoV-2 coronavirus, the scientist said in statements to the TASS news agency.

He noted that the effectiveness of the US drug 'has been reduced by half, almost to 50-40 percent, which is not observed in Sputnik V, so the proposal of the Russian Direct Investment Fund (RDIF) is quite logical and it has scientific bases.'

On August 11th, the RDIF launched the proposal to use Sputnik Light in the third doses for those vaccinated with Pfizer. Also last autumn, RDIF proposed, in particular, cooperation with the British-Swedish company AstraZeneca.

They reported that Pfizer's effectiveness dropped from 76 percent to 42 percent owing to the widespread prevalence of the Delta strain.
The Russian Health Ministry explained earlier that the effectiveness of Sputnik V against this strain is 83 percent. Sputnik Light is the first component of this vaccine.

In the meantime, the New England Journal of medicine seems to contradict the Russian take on the Pfizer vaccine, reporting that Two doses of Pfizer  or AstraZeneca's  COVID-19 vaccine are nearly as effective against the highly transmissible Delta coronavirus variant as they are against the previously dominant Alpha variant, a study published on Wednesday showed.

Officials say vaccines are highly effective against the Delta variant, now the dominant variant worldwide, though the study reiterated that one shot of the vaccines is not enough for high protection.

The study, published in the New England Journal of Medicine, confirms headline findings given by Public Health England in May about the efficacy of COVID-19 vaccines made by Pfizer-BioNTech and Oxford-AstraZeneca, based on real-world data.

Wednesday's study found that two doses of Pfizer's shot was 88% effective at preventing symptomatic disease from the Delta variant, compared to 93.7% against the Alpha variant, broadly the same as previously reported.

Two shots of AstraZeneca vaccine were 67% effective against the Delta variant, up from 60% originally reported, and 74.5% effective against the Alpha variant, compared to an original estimate of 66% effectiveness.

"Only modest differences in vaccine effectiveness were noted with the Delta variant as compared with the Alpha variant after the receipt of two vaccine doses," Public Health England researchers wrote in the study.

Data from Israel has estimated lower effectiveness of Pfizer's shot against symptomatic disease, although protection against severe disease remains high.

PHE had previously said that a first dose of either vaccine was around 33% effective against symptomatic disease from the Delta variant.

Author’s Posts